Monday, April 25, 2016

Hua Medicine Gets $50M

San Francisco- and Shanghai-based Hua Medicine, a developer of treatments for diabetes, says it has raised $50M in a Series C financing. The funding was led by Harvest Investments, and also included Frontline BioVentures, ARCH, Venrock, Fidelity, WuXi Ventures, SAIl, ALly Bridge Group, and TF Capital. The company said it was advised by China Renaissance in the funding. Hua Medicine is led by CEO Li Chen.